{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:10:52Z","timestamp":1776737452172,"version":"3.51.2"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00431-010-1265-9","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T03:23:05Z","timestamp":1280892185000},"page":"309-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Position paper\u2014HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians"],"prefix":"10.1007","volume":"170","author":[{"given":"Jos\u00e9","family":"Ramet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"van Esso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsofia","family":"Meszner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the European Academy of Paediatrics Scientific Working Group on Vaccination","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,5]]},"reference":[{"key":"1265_CR1","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (2008) Gardasil\u00ae: first assessment of risk surveillance in France. Press release, 15 July"},{"issue":"15","key":"1265_CR2","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.ejca.2009.07.020","volume":"45","author":"A Anttila","year":"2009","unstructured":"Anttila A, von Karsa L, Aasmaa A, Fender M, Patnick J, Rebolj M, Nicula F, Vass L, Valerianova Z, Voti L, Sauvaget C, Ronco G (2009) Cervical cancer screening policies and coverage in Europe. Eur J Cancer 45(15):2649\u20132658","journal-title":"Eur J Cancer"},{"key":"1265_CR3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archotol.125.7.743","volume":"125","author":"LR Armstrong","year":"1999","unstructured":"Armstrong LR, Derkay CS, Reeves WC, the RRP Task Force (1999) Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otol Head Neck Surg 125:743\u2013748","journal-title":"Arch Otol Head Neck Surg"},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","author":"Ault KA, FUTURE II Study Group","year":"2007","unstructured":"Ault KA, FUTURE II Study Group (2007) Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four clinical trials. Lancet 369:1861\u20131968","journal-title":"Lancet"},{"key":"1265_CR5","unstructured":"Australian Government, Department of Health and Aging Therapeutic Goods Administration (2008) Human papillomavirus vaccine (GARDASIL). http:\/\/www.tga.gov.au\/alerts\/medicines\/gardasil.htm. Accessed 27 July 2010"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1086\/520654","volume":"45","author":"E Barr","year":"2007","unstructured":"Barr E, Tamms G (2007) Quadrivalent human papillomavirus vaccine. Clin Infect Dis 45:609\u2013617","journal-title":"Clin Infect Dis"},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1542\/peds.2006-0461","volume":"118","author":"SL Block","year":"2006","unstructured":"Block SL, Nolan T, Sattler C et al (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135\u20132145","journal-title":"Pediatrics"},{"key":"1265_CR8","unstructured":"BMGF (2006) Recommendations of the Superior Austrian Medical Council. Vaccination Committee, 21 November, http:\/\/www.bmgf.gv.at. Accessed 27 July 2010"},{"key":"1265_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","volume":"31","author":"FX Bosch","year":"2003","unstructured":"Bosch FX, de Sanjos\u00e9 S (2003) Chapter 1: human papillomavirus and cervical cancer\u2014burden and assessment of causality. J Natl Cancer Inst Monogr 31:3\u201313","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1265_CR10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"FX Bosch","year":"2002","unstructured":"Bosch FX, Lorincz A, Mu\u00f1oz N, Meijer CJLM, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244\u2013265","journal-title":"J Clin Pathol"},{"key":"1265_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/S0264-410X(97)00068-6","volume":"15","author":"M B\u00f6ttiger","year":"1997","unstructured":"B\u00f6ttiger M, Forsgren M (1997) Twenty years\u2019 experience of rubella vaccination in Sweden: 10\u00a0years of selective vaccination (of 12-year-old girls and of women postpartum) and 13\u00a0years of a general two-dose vaccination. Vaccine 15:1538\u20131544","journal-title":"Vaccine"},{"key":"1265_CR12","first-page":"1","volume":"391","author":"M Bozon","year":"2003","unstructured":"Bozon M (2003) At what age do women and men have their first sexual intercourse? World comparisons and recent trends. Popul Soc 391:1\u20134","journal-title":"Popul Soc"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","volume":"14","author":"F Bray","year":"2005","unstructured":"Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14:2191\u20132199","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1265_CR14","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","volume":"37","author":"DR Brown","year":"1999","unstructured":"Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH (1999) Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 37:3316\u20133322","journal-title":"J Clin Microbiol"},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1086\/426867","volume":"191","author":"DR Brown","year":"2005","unstructured":"Brown DR, Shew ML, Qadadri B et al (2005) A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191:182\u2013192","journal-title":"J Infect Dis"},{"key":"1265_CR16","doi-asserted-by":"crossref","unstructured":"Castellsagu\u00e9 X, Munoz N (2003) Chapter 3: cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 20\u201328","DOI":"10.1093\/oxfordjournals.jncimonographs.a003477"},{"key":"1265_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jnci\/djj067","volume":"98","author":"X Castellsagu\u00e9","year":"2006","unstructured":"Castellsagu\u00e9 X, D\u00edaz M, de Sanjos\u00e9 S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303\u2013315","journal-title":"J Natl Cancer Inst"},{"key":"1265_CR18","unstructured":"Centers for Disease Control (2008) Reports of health concerns following HPV vaccination. HPV vaccine safety. http:\/\/www.cdc.gov\/vaccinesafety\/Vaccines\/HPV\/gardasil.html. Accessed 27 July 2010"},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1101\/gad.9.19.2335","volume":"9","author":"S Cheng","year":"1995","unstructured":"Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT (1995) Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 9:2335\u20132349","journal-title":"Genes Dev"},{"key":"1265_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","volume":"366","author":"GM Clifford","year":"2005","unstructured":"Clifford GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991\u2013998","journal-title":"Lancet"},{"issue":"Suppl 3","key":"1265_CR21","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.vaccine.2006.05.026","volume":"24","author":"G Clifford","year":"2006","unstructured":"Clifford G, Franceschi S, Diaz M, Mu\u00f1oz N, Villa LL (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24(Suppl 3):S26\u2013S34","journal-title":"Vaccine"},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1471-0528.2002.01053.x","volume":"109","author":"S Collins","year":"2002","unstructured":"Collins S, Mazloomzadeh S, Winter H et al (2002) High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109:96\u201398","journal-title":"BJOG"},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cncr.20365","volume":"101","author":"JR Daling","year":"2004","unstructured":"Daling JR, Madeleine MM, Johnson LG et al (2004) Human papillomavirus, smoking and sexual practices in the etiology of anal cancer. Cancer 101:270\u2013280","journal-title":"Cancer"},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","volume":"7","author":"S de Sanjos\u00e9","year":"2007","unstructured":"de Sanjos\u00e9 S, Diaz M, Castellsagu\u00e9 X et al (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7:453\u2013459","journal-title":"Lancet Infect Dis"},{"key":"1265_CR25","first-page":"57","volume":"12","author":"EM De Villiers","year":"2001","unstructured":"De Villiers EM (2001) Taxonomic classification of papillomaviruses. Papillomavirus Rep 12:57\u201367","journal-title":"Papillomavirus Rep"},{"key":"1265_CR26","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archotol.1995.01890120044008","volume":"121","author":"CS Derkay","year":"1995","unstructured":"Derkay CS (1995) Task force on recurrent respiratory papillomas. A preliminary report. Arch Otol Head Neck Surg 121:1386\u20131391","journal-title":"Arch Otol Head Neck Surg"},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1042\/CS20050369","volume":"110","author":"J Doorbar","year":"2006","unstructured":"Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110:525\u2013541","journal-title":"Clin Sci (Lond)"},{"key":"1265_CR28","unstructured":"European Medicines Agency (2008) EMEA statement on the safety of Gardasil. 24 January"},{"key":"1265_CR29","unstructured":"FDA (2009) Approval letter\u2014Gardasil October 16, 2009. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm186991.htm. Accessed 27 July 2010"},{"key":"1265_CR30","volume-title":"GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5. version 2.0","year":"2004","unstructured":"Ferlay J, Bray F, Pisani P et al (eds) (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5. version 2.0. IARC, Lyon"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1016\/j.vaccine.2007.10.005","volume":"25","author":"D FitzSimons","year":"2007","unstructured":"FitzSimons D, Vorsters A, Hoppenbrouwers K, Van Damme P (2007) Prevention and control of viral hepatitis through adolescent health programmes in Europe. Vaccine 25:8651\u20138659","journal-title":"Vaccine"},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928\u20131943","journal-title":"N Engl J Med"},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1086\/341782","volume":"186","author":"AR Giuliano","year":"2002","unstructured":"Giuliano AR, Harris R, Sedjo RL et al (2002) Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women\u2019s Health Study. J Infect Dis 186:462\u2013469","journal-title":"J Infect Dis"},{"key":"1265_CR34","unstructured":"GlaxoSmithKline Biologicals s.a. (2008) Cervarix summary of product characteristics. August"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/01.AOG.0000245786.86267.80","volume":"108","author":"M Hampl","year":"2006","unstructured":"Hampl M, Sarajuuri H, Wentzensen N et al (2006) Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 108:1361\u20131368","journal-title":"Obstet Gynecol"},{"key":"1265_CR36","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"DM Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757\u20131765","journal-title":"Lancet"},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler C et al (2006) sustained efficacy up to 4.5\u00a0years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247\u20131255","journal-title":"Lancet"},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"GY Ho","year":"1998","unstructured":"Ho GY, Bierman R, Beardsley L et al (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423\u2013428","journal-title":"N Engl J Med"},{"key":"1265_CR39","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","volume":"369","author":"EA Joura","year":"2007","unstructured":"Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693\u20131702","journal-title":"Lancet"},{"key":"1265_CR40","unstructured":"Joura E, FUTURE I and II Study Group (2008) Sustained protection by quadrivalent HPV (type 6, 11, 16, 18) vaccine through 4\u00a0years against HPV 6\/11\/16\/18-related cervical intraepithelial neoplasia grade 2\/3 (CIN2\/3) and adenocarcinoma (AIS) of the cervix. Clinical Symposium on Cervical Cancer, presented at the 19th International Conference on Anti-cancer Treatment, Paris, France, 5\u20138 February (Abstract)"},{"key":"1265_CR41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/01.AOG.0000210268.57527.a1","volume":"107","author":"PL Judson","year":"2006","unstructured":"Judson PL, Habermann EB, Baxter NN et al (2006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018\u20131022","journal-title":"Obstet Gynecol"},{"key":"1265_CR42","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/1055-9965.EPI-04-0754","volume":"14","author":"SK Kjaer","year":"2005","unstructured":"Kjaer SK, Munk C, Winther JF et al (2005) Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomark Prev 14:1528\u20131533","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","volume":"2","author":"SK Kjaer","year":"2009","unstructured":"Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson S-E, Tang GWK, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2:868\u2013878","journal-title":"Cancer Prev Res"},{"key":"1265_CR44","unstructured":"Lacey CJN, GARDASIL Phase III Investigators (2008) Continued efficacy of quadrivalent HPV (types 6\/11\/16\/18) L1 VLP vaccine in preventing cervical or external genital disease: 4\u00a0years of follow-up. 20th European College of Obstetrics and Gynecology, Lisbon, Portugal, 4\u20138 March (Abstract)"},{"key":"1265_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/MMBR.68.2.362-372.2004","volume":"68","author":"MS Longworth","year":"2004","unstructured":"Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362\u2013372","journal-title":"Microbiol Mol Biol Rev"},{"key":"1265_CR46","unstructured":"MHRA (2009) Cervarix, UK. http:\/\/www.mhra.gov.uk\/home\/groups\/pl-a\/documents\/websiteresources\/con059936.pdf. Accessed 27 July 2010"},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"10186","DOI":"10.1128\/JVI.77.19.10186-10201.2003","volume":"77","author":"K Middleton","year":"2003","unstructured":"Middleton K, Peh W, Southern S et al (2003) Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77:10186\u201310201","journal-title":"J Virol"},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0022-3476(98)70445-7","volume":"132","author":"AB Moscicki","year":"1998","unstructured":"Moscicki AB, Shiboski S, Broering J et al (1998) The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132:277\u2013284","journal-title":"J Pediatr"},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0168-1702(02)00190-9","volume":"89","author":"K M\u00fcnger","year":"2002","unstructured":"M\u00fcnger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89:213\u2013228","journal-title":"Virus Res"},{"key":"1265_CR50","doi-asserted-by":"publisher","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","volume":"78","author":"K M\u00fcnger","year":"2004","unstructured":"M\u00fcnger K, Baldwin A, Edwards KM et al (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451\u201311460","journal-title":"J Virol"},{"key":"1265_CR51","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz N, Bosch FX, de Sanjos\u00e9 S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518\u2013527","journal-title":"N Engl J Med"},{"key":"1265_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ijc.20244","volume":"111","author":"N Mu\u00f1oz","year":"2004","unstructured":"Mu\u00f1oz N, Bosch FX, Castellsagu\u00e9 X et al (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278\u2013285","journal-title":"Int J Cancer"},{"key":"1265_CR53","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1086\/425907","volume":"190","author":"N Mu\u00f1oz","year":"2004","unstructured":"Mu\u00f1oz N, M\u00e9ndez F, Posso H et al (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Columbian women with normal cytological results. J Infect Dis 190:2077\u20132087","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"1265_CR54","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.vaccine.2006.05.115","volume":"24","author":"N Mu\u00f1oz","year":"2006","unstructured":"Mu\u00f1oz N, Castellsagu\u00e9 X, Berrington de Gonz\u00e1lez A, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl 3):S1\u2013S10","journal-title":"Vaccine"},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","volume":"25","author":"SE Olsson","year":"2007","unstructured":"Olsson SE, Villa LL, Costa RL, Petta CA et al (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931\u20134939","journal-title":"Vaccine"},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3122\/jabfm.18.1.13","volume":"18","author":"NV Oster","year":"2005","unstructured":"Oster NV, McPhillips-Tangum CA, Averhoff F, Howell K (2005) Barriers to adolescent immunization: a survey of family physicians and pediatricians. J Am Board Fam Pract 18:13\u201319","journal-title":"J Am Board Fam Pract"},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161\u20132170","journal-title":"Lancet"},{"key":"1265_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmeron J et al (2009) Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301\u2013314","journal-title":"Lancet"},{"key":"1265_CR59","volume-title":"Cancer incidence in five continents, vol. VIII. IARC Scientific Publications no. 155","author":"DM Parkin","year":"2002","unstructured":"Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents, vol. VIII. IARC Scientific Publications no. 155. IARC, Lyon"},{"key":"1265_CR60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","volume":"40","author":"C Pedersen","year":"2007","unstructured":"Pedersen C, Petaja T, Strauss G et al (2007) Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40:564\u2013571","journal-title":"J Adolesc Health"},{"key":"1265_CR61","doi-asserted-by":"publisher","first-page":"10401","DOI":"10.1128\/JVI.76.20.10401-10416.2002","volume":"76","author":"WL Peh","year":"2002","unstructured":"Peh WL, Middleton K, Christensen N et al (2002) Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol 76:10401\u201310416","journal-title":"J Virol"},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","volume":"364","author":"J Peto","year":"2004","unstructured":"Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364:249\u2013256","journal-title":"Lancet"},{"key":"1265_CR63","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/bmj.318.7188.904","volume":"318","author":"M Quinn","year":"1999","unstructured":"Quinn M, Babb P, Jones J, Allen E, on behalf of the United Kingdom Association of Cancer Registries (1999) Effect of screening on incidence of and mortality from cancer or cervix in England: evaluation based on routinely collected statistics. BMJ 318:904\u2013908","journal-title":"BMJ"},{"key":"1265_CR64","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1001\/archotol.129.9.976","volume":"129","author":"WC Reeves","year":"2003","unstructured":"Reeves WC, Ruparelia SS, Swanson KI et al (2003) National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 129:976\u2013982","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1265_CR65","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/1055-9965.EPI-08-0965","volume":"18","author":"LL Reimers","year":"2009","unstructured":"Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE (2009) Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomark Prev 18:792\u2013800","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1265_CR66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","volume":"26","author":"KS Reisinger","year":"2007","unstructured":"Reisinger KS, Block SL, Lazcano-Ponce E et al (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26:201\u2013209","journal-title":"Pediatr Infect Dis J"},{"key":"1265_CR67","first-page":"485","volume":"12","author":"H Richardson","year":"2003","unstructured":"Richardson H, Kelsall G, Tellier P et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomark Prev 12:485\u2013490","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1265_CR68","unstructured":"Ross J, Godeau E, Dias S (2004) Sexual health. In: Currie C, Roberts C, Morgan A, et al. (eds) Young people\u2019s health in context. Health behaviour in School-aged Children (HSBC) study: international report from the 2001\/2002 survey. Health policy for children and adolescents, no. 4. World Health Organization, pp 153\u2013160"},{"key":"1265_CR69","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0002-9440(10)62506-0","volume":"159","author":"MA Rubin","year":"2001","unstructured":"Rubin MA, Kleter B, Zhou M et al (2001) Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159:1211\u20131218","journal-title":"Am J Pathol"},{"key":"1265_CR70","unstructured":"Sanofi Pasteur MSD (2008) Gardasil summary of product characteristics. September"},{"key":"1265_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","volume":"337","author":"M Schiffman","year":"2005","unstructured":"Schiffman M, Herrero R, DeSalle R et al (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76\u201384","journal-title":"Virology"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0029-7844(02)03081-8","volume":"101","author":"MJ Silverberg","year":"2003","unstructured":"Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV (2003) Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 101:645\u2013652","journal-title":"Obstet Gynecol"},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/archotol.130.6.711","volume":"130","author":"MJ Silverberg","year":"2004","unstructured":"Silverberg MJ, Thorsen P, Lindeberg H et al (2004) Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg 130:711\u2013716","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1265_CR74","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/gyno.2000.5826","volume":"78","author":"HO Smith","year":"2000","unstructured":"Smith HO, Tiffany MF, Qualls CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States\u2014a 24-year population-based study. Gynecol Oncol 78:97\u2013105","journal-title":"Gynecol Oncol"},{"key":"1265_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ijc.22527","volume":"121","author":"JS Smith","year":"2007","unstructured":"Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621\u2013632","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"1265_CR76","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.vaccine.2006.05.110","volume":"24","author":"M Stanley","year":"2006","unstructured":"Stanley M (2006) Immune responses to human papillomavirus. Vaccine 24(Suppl 1):S106\u2013S113","journal-title":"Vaccine"},{"key":"1265_CR77","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"The FUTURE II Study Group","year":"2007","unstructured":"The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915\u20131927","journal-title":"N Engl J Med"},{"key":"1265_CR78","unstructured":"The Protocol 024 Investigators (2008) An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of a quadrivalent HPV 6\/11\/16\/18 vaccine (GARDASIL\u2122) given concomitantly with REPEVAX\u2122 in healthy adolescents 11\u201317\u00a0years of age. In: 6th European Conference of Infectious Diseases in Obstetrics and Gynecology, 28\u201331 August, Leuven, Belgium (Abstract)"},{"key":"1265_CR79","volume-title":"A complex picture HIV and other sexually transmitted infections in the United Kingdom: 2006","author":"The UK Collaborative Group for HIV and STI Surveillance","year":"2006","unstructured":"The UK Collaborative Group for HIV and STI Surveillance (2006) A complex picture HIV and other sexually transmitted infections in the United Kingdom: 2006. Health Protection Agency, Centre for Infections, London, November"},{"key":"1265_CR80","unstructured":"VAERS (2010) Gardasil, US. http:\/\/www.medalerts.org\/vaersdb\/index.html. Accessed 27 July 2010"},{"key":"1265_CR81","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","volume":"24","author":"LL Villa","year":"2006","unstructured":"Villa LL, Ault KA, Giuliano AR et al (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24:5571\u20135583","journal-title":"Vaccine"},{"key":"1265_CR82","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U","volume":"75","author":"AP Vizcaino","year":"1998","unstructured":"Vizcaino AP, Moreno V, Bosch FX et al (1998) International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 75:536\u2013545","journal-title":"Int J Cancer"},{"key":"1265_CR83","first-page":"598","volume":"11","author":"G von Krogh","year":"2001","unstructured":"von Krogh G (2001) Management of anogenital warts (condylomata acuminata). Eur J Dermatol 11:598\u2013603","journal-title":"Eur J Dermatol"},{"key":"1265_CR84","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12\u201319","journal-title":"J Pathol"},{"issue":"10 suppl","key":"1265_CR85","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1002\/cncr.23756","volume":"113","author":"M Watson","year":"2008","unstructured":"Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, Schwenn M, Huang Y, Giuliano A (2008) Burden of cervical cancer in the United States, 1998\u20132003. Cancer 113(10 suppl):2855\u20132864","journal-title":"Cancer"},{"key":"1265_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69479-8","author":"K Wellings","year":"2006","unstructured":"Wellings K, Collumbien M, Slaymaker E, Singh S, Patel D, Bajos N (2006) Sexual behaviour in context: a global perspective. Lancet. doi:10.1016\/S0140-6736(06)69479-8","journal-title":"Lancet"},{"key":"1265_CR87","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","volume":"26","author":"CM Wheeler","year":"2008","unstructured":"Wheeler CM, Bautista OM, Tomassini JE et al (2008) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26:686\u2013696","journal-title":"Vaccine"},{"key":"1265_CR88","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/aje\/kwf180","volume":"157","author":"RL Winer","year":"2003","unstructured":"Winer RL, Lee SK, Hughes JP et al (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157:218\u2013226","journal-title":"Am J Epidemiol"},{"key":"1265_CR89","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1128\/jvi.68.9.6097-6102.1994","volume":"68","author":"X Wu","year":"1994","unstructured":"Wu X, Xiao W, Brandsma JL (1994) Papilloma formation by cottontail rabbit papillomavirus requires E1 and E2 regulatory genes in addition to E6 and E7 transforming genes. J Virol 68:6097\u20136102","journal-title":"J Virol"},{"key":"1265_CR90","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/infdis\/172.3.747","volume":"172","author":"LF Xi","year":"1995","unstructured":"Xi LF, Demers GW, Koutsky LA et al (1995) Analysis of human papillomavirus type 16 variants indicates establishment of persistent infections. J Infect Dis 172:747\u2013755","journal-title":"J Infect Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-010-1265-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-010-1265-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-010-1265-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-010-1265-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T21:27:07Z","timestamp":1659043627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-010-1265-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,5]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s00431-010-1265-9","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,5]]},"assertion":[{"value":"24 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}